SCHEMBL5322126

SCHEMBL5322126

CC1CN(C(=O)c2ccccc2)CCN1S(=O)(=O)c1cccs1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCKR Q14397 2/20 0.51
LMNA P02545 2/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
HSD17B10 Q99714 1/20 0.50
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 2/20 0.47
RAB9A P51151 1/20 0.47
POLB P06746 1/20 0.45
HTT P42858 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PKM P14618 6/20 0.45
MMP1 P03956 1/20 0.44
MMP3 P08254 1/20 0.44
MMP7 P09237 1/20 0.44
MMP9 P14780 1/20 0.44
MMP13 P45452 1/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5652990 0.86 KDM4E (0.44) GCKRLMNAALOX15TSHRHSD17B10
SCHEMBL14367061 0.85 LMNA (0.50) GCKRLMNAALOX15TSHRHSD17B10
SCHEMBL5652276 0.82 LMNA (0.52) LMNAALOX15TSHRHSD17B10KMT2A
SCHEMBL14367034 0.82 LMNA (0.52) LMNAALOX15TSHRHSD17B10KMT2A
SCHEMBL5322626 0.82 MAPT (0.49) LMNATSHRHSD17B10ALDH1A1POLB
SCHEMBL5326286 0.82 MAPT (0.49) LMNATSHRHSD17B10ALDH1A1POLB
SCHEMBL5322548 0.82 MMP1 (0.43) HTTMMP1MMP3MMP7MMP9
SCHEMBL5652538 0.81 SMO (0.45) HTTMMP1MMP3MMP7MMP9
SCHEMBL5319968 0.80 CYP2D6 (0.42) HTTMMP1MMP3MMP7MMP9
SCHEMBL5320715 0.80 GCKR (0.52) GCKRLMNAALOX15TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 US disclosed
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 US disclosed
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 US disclosed
WO-2007103456-A2 PIPERAZINE AND PIPERIDINE BIARYL DERIVATIVES TRIMERIS, INC. (US) 2007-09-13 WO disclosed
WO-2007103456-A2 PIPERAZINE AND PIPERIDINE BIARYL DERIVATIVES TRIMERIS, INC. (US) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259879-A1 Piperazine and piperidine biaryl derivatives CYP3A5, CYP3A43, CCR5 GCKR 2871/4885LMNA 2555/4885ALOX15 2741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.